1. Home
  2. RCBC vs PHAT Comparison

RCBC vs PHAT Comparison

Compare RCBC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo River City Bank Common stock

RCBC

River City Bank Common stock

N/A

Current Price

$55.72

Market Cap

736.3M

Sector

Finance

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

SELL

Current Price

$7.06

Market Cap

590.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RCBC
PHAT
Founded
1963
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
736.3M
590.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RCBC
PHAT
Price
$55.72
$7.06
Analyst Decision
Hold
Buy
Analyst Count
4
12
Target Price
★ $56.00
$20.45
AVG Volume (30 Days)
89.4K
★ 1.2M
Earning Date
10-23-2026
10-29-2026
Dividend Yield
★ 0.36%
N/A
EPS Growth
N/A
★ 42.72
EPS
★ N/A
N/A
Revenue
N/A
★ $175,110,000.00
Revenue This Year
N/A
$80.58
Revenue Next Year
$2.45
$56.62
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 216.93
52 Week Low
$46.34
$6.52
52 Week High
$56.71
$18.31

Technical Indicators

Market Signals
Indicator
RCBC
PHAT
Relative Strength Index (RSI) 73.20 39.36
Support Level $50.77 $6.91
Resistance Level N/A $9.74
Average True Range (ATR) 1.40 0.31
MACD 0.27 0.07
Stochastic Oscillator 85.99 54.59

Price Performance

Historical Comparison
RCBC
PHAT

About RCBC River City Bank Common stock

River City Bank is a California state-chartered bank engaged in providing a range of banking services to individuals and businesses in California. The company's primary deposit products are checking, savings, and term certificate accounts, and its primary lending products are commercial real estate, commercial, agriculture, residential mortgage, and consumer loans. Substantially all loans are secured by specific items of collateral, including business assets, consumer assets, and commercial and residential real estate in the Western United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: